Lantheus (NASDAQ:LNTH) Stock Sale Revealed by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Lantheus Holdings, Inc. (NASDAQ:LNTH). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Lantheus stock on October 15th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

Lantheus Stock Performance

NASDAQ LNTH traded down $0.35 during trading hours on Thursday, reaching $101.25. The stock had a trading volume of 1,193,845 shares, compared to its average volume of 1,084,147. The stock has a fifty day moving average of $100.30 and a 200 day moving average of $92.57. The stock has a market cap of $6.62 billion, a P/E ratio of 24.94 and a beta of 0.01. Lantheus Holdings, Inc. has a 52-week low of $51.47 and a 52-week high of $111.86. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.06 and a current ratio of 3.25.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.45. Lantheus had a net margin of 17.28% and a return on equity of 29.26%. The company had revenue of $389.91 million for the quarter, compared to the consensus estimate of $355.74 million. During the same quarter in the prior year, the company earned $1.27 EPS. Lantheus’s quarterly revenue was up 1.5% on a year-over-year basis. Sell-side analysts predict that Lantheus Holdings, Inc. will post 4.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on LNTH shares. Leerink Partners set a $102.50 target price on shares of Lantheus in a research report on Monday, August 3rd. CJS Securities downgraded Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. Weiss Ratings downgraded Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, October 15th. TD Cowen lowered Lantheus from a “buy” rating to a “hold” rating and reduced their price objective for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. Finally, Mizuho cut Lantheus from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $115.00 to $109.00 in a report on Tuesday, October 13th. Three research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat, Lantheus presently has an average rating of “Hold” and a consensus price target of $107.44.

Institutional Trading of Lantheus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jupiter Topco LLC acquired a new stake in shares of Lantheus during the 2nd quarter valued at about $575,628,000. ABS Investment Management LLC purchased a new stake in shares of Lantheus in the second quarter valued at approximately $232,974,000. Reinhart Partners LLC. lifted its position in shares of Lantheus by 2.2% during the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock valued at $177,437,000 after buying an additional 34,501 shares in the last quarter. Carmignac Gestion grew its stake in Lantheus by 0.9% in the 2nd quarter. Carmignac Gestion now owns 1,340,100 shares of the medical equipment provider’s stock valued at $148,671,000 after acquiring an additional 12,100 shares during the period. Finally, Assenagon Asset Management S.A. raised its position in Lantheus by 440.3% during the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock worth $79,320,000 after acquiring an additional 582,661 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Lantheus Company Profile

Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.